← My Government dashboard

Government Watch

Dossier D.C. Cir. circuit opinion 21-jul-2026
A U.S. Court of Appeals ruling — binding precedent within that circuit, persuasive elsewhere.

Novartis Pharmaceuticals Corporation v. Robert Kennedy, Jr.

Key claim: The U.S. Court of Appeals for the D.C. Circuit issued an opinion on July 21, 2026 in Novartis Pharmaceuticals Corporation v. Robert Kennedy, Jr.

Abstract

U.S. Court of Appeals for the D.C. Circuit opinion decided 2026-07-21.

Why this matters

D.C. Circuit rulings in pharmaceutical manufacturer challenges to HHS are the principal appellate venue for shaping how far federal drug-pricing statutes (notably the IRA Medicare Drug Price Negotiation Program) can reach manufacturers. Even without disclosed holdings, a Novartis appellate opinion is a marker for how courts are treating industry constitutional and statutory challenges that could alter what Medicare pays and what beneficiaries face at the pharmacy counter.

Source

Link

Briefing card

Novartis Pharmaceuticals Corporation v. Robert Kennedy, Jr.
Stage: circuit opinion · cadc · 21-jul-2026

The U.S. Court of Appeals for the D.C. Circuit issued an opinion on July 21, 2026 in Novartis Pharmaceuticals Corporation v. Robert Kennedy, Jr.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: courtlistener:cadc:10933372

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Stages other doctrine resolution introduced proposed rule passed chamber executive action final rule enacted district opinion circuit opinion opinion

Subscribe: calendar of upcoming dates · deadlines feed · all new records

build build 392 · ea9c128-dirty · 2026-08-09